| Literature DB >> 26675014 |
Ilona Gyuleva1, Delyana Panova1, Jana Djounova1, Ivanka Rupova1, Kalina Penkova2.
Abstract
The purpose of this article is to analyze the results of a 10-year survey of the radiation effects of some immune parameters of occupationally exposed personnel from the Nuclear Power Plant "Kozloduy", Bulgaria. 438 persons working in NPP with cumulative doses between 0.06 mSv and 766.36mSv and a control group with 65 persons were studied. Flow cytometry measurements of T, B, natural killer (NK) and natural killer T (NKT) cell lymphocyte populations were performed. Data were interpreted with regard to cumulative doses, length of service and age. The average values of the studied parameters of cellular immunity were in the reference range relative to age and for most of the workers were not significantly different from the control values. Low doses of ionizing radiation showed some trends of change in the number of CD3+CD4+ helper-inducer lymphocytes, CD3+ CD8+ and NKT cell counts. The observed changes in some of the studied parameters could be interpreted in terms of adaptation processes at low doses. At doses above 100-200 mSv, compensatory mechanisms might be involved to balance deviations in lymphocyte subsets. The observed variations in some cases could not be attributed only to the radiation exposure because of the impact of a number of other exogenous and endogenous factors on the immune system.Entities:
Keywords: Immunology; flowcytometry; ionising radiation; low-dose effects; lymphocytes
Year: 2015 PMID: 26675014 PMCID: PMC4674168 DOI: 10.2203/dose-response.14-041.Gyuleva
Source DB: PubMed Journal: Dose Response ISSN: 1559-3258 Impact factor: 2.658
NPP personnel: groups according to received doses, average age and length of employment.
| Personnel | Average age (years) * | Length of service (years) * | Received dose (mSv) * | ||
|---|---|---|---|---|---|
| Group | Dose (mSv) | n | |||
| Control | 0 | 65 (49 male and 16 female) | 46 ± 8 | 19 ± 8 | 0 |
| 1 | 0.1–20 | 103 (93 male and 10 female) | 43 ± 7 | 16 ± 8 | 9.53 ± 5.8 |
| 2 | 20.1–100 | 117 (112 male and 5 female) | 42 ± 8 | 16 ± 8 | 49.42 ± 21.7 |
| 3 | 100.1–200 | 66 (64 male and 2 female) | 45 ± 7 | 18 ± 6 | 141.95 ± 30.4 |
| 4 | >200 | 153 (male) | 45 ± 6 | 20 ± 6 | 354.48 ± 120.3 |
*Indicate the standard deviation (±SD).
General health status of NPP workers
| Groups* | ||||||
|---|---|---|---|---|---|---|
| Condition | Health status | Control (%) | 0.1–20 mSv (%) | 20–100 mSv (%) | 100–200 mSv (%) | > 200 mSv (%) |
| Mobius hypertonicus | healthy | 81.8 | 66.7 | 64.5 | 68.4 | 62.1 |
| with disease | 18.2 | 33.3 | 35.5 | 31.6 | 37.9 | |
| Cardio vascular diseases | healthy | 78.8 | 66.7 | 64.5 | 63.2 | 62.1 |
| with disease | 21.2 | 33.3 | 35.5 | 36.8 | 37.9 | |
| Obesities | healthy | 84.8 | 85.2 | 74.2 | 57.9 | 93.1 |
| with disease | 15.2 | 1 4.8 | 25.8 | 42.1 | 6.9 | |
| Diabetes mellitus | healthy | 97.0 | 92.6 | 96.8 | 100.0 | 96.6 |
| with disease | 3.0 | 7.4 | 3.2 | - | 3.4 | |
| Hepatitis (inactive. not chronic) | healthy | 97.0 | 88.9 | 90.3 | 89.5 | 93.1 |
| with disease | 3.0 | 11.1 | 9.7 | 10.5 | 6.9 | |
| Vaccinations and virus diseases in last month Gastrointestinal diseases | no | 84.8 | 85.2 | 93.5 | 89.5 | 89.7 |
| yes | 15.2 | 14.8 | 6.5 | 10.5 | 10.3 | |
| healthy | 89.2 | 93.6 | 93.4 | 94.9 | 94.1 | |
| with disease | 10.8 | 6.4 | 6.6 | 5.1 | 5.9 | |
| Pulmonary diseases | healthy | 100.0 | 96.8 | 97.8 | 96.6 | 97.4 |
| with disease | - | 3.2 | 2.2 | 3.4 | 2.6 | |
*Data are presented as percent of all individuals in each group.
Reference values* for lymphocyte subsets as percentage of lymphocyte count
| Indices | Percentage values (%) | Absolute values (×109) |
|---|---|---|
| CD3+ | 61–85 | 1000–2000 cells/μl |
| CD3+4+ | 34–59 | 560–1410 cells/μl |
| CD3+8+ | 19–36 | 320–960 cells/μl |
|
| - | 1.1–2.8 |
| CD19+ | 6–15 | 110–390 cells/μl |
| CD3-16+56+ | 7–26 | 110–620 cells/μl |
| CD3+CD16+CD56+ | 3–10 | 44–356 cells/μl |
| CD57+CD8- | 3–13 | 44–400 cells/μl |
| CD57+CD8+ | 5–11 | 9–257 cells/μl |
*Reference values for the Bulgarian population is 5th percentile to 95th percentile range by data of Central Laboratory of Clinical Immunology, University Hospital Alexandrovska, Sofia, Bulgaria (Naumova E and Altankova I. 2001)
Variation analysis of percentage of B, total, helper-inducer, cytotoxic-suppressor T lymphocyte and NK and NKT cell in NPP workers
| Parameters,Groups,mSv | B lymphocytes (CD19+) X ± SD (%) | Total T lymphocytes (CD 3+) X ± SD (%) | Helper- inducer T lymphocytes (CD3+CD4+) X ± SD (%) | Cytotoxic- suppressor T lymphocytes (CD3+CD8+) X ± SD (%) | CD4±/CD8± ratio X ± SD | NK cells (CD3-CD16± CD56±) X ± SD (%) | NK cells with phenotype (CD57±CD8-) X ± SD (%) | NKT cells (CD3±CD16± CD56±) X ± SD (%) | T lymphocytes with NK activity (CD57±CD8±) X ± SD (%) |
|---|---|---|---|---|---|---|---|---|---|
| Control 0.0 | 9.80 ± 3.4 | 72.08 ± 5.9 | 44.19 ± 6.5 | 26.34 ±6.7 | 1.78 ±0.6 | 16.58 ± 6.0 | 6.67 ± 4.8 | 5.48 ±5.1 | 12.45 ±5.2 |
| Group 1 0.1 –20 | 9.72 ± 3.7 | 71.65 ±8.3 | 40.35 ± 9.0 | 29.66 ± 8.9 | 1.54±0.76 | 16.90 ± 7.8 | 8.11 ± 6.4 | 7.94 ± 7.4 | 17.78 ±7.9* |
| Group 2 20.1–100 | 9.98 ± 4.2 | 70.24 ±8.1 | 41.33 ± 7.9 | 26.86 ± 8.3 | 1.72 ±0.7 | 17.79 ± 7.8 | 6.76 ±4.1 | 8.94 ± 8.3 | 16.03 ± 7.8 |
| Group 3 100.1 –200 | 10.56 ± 4.8 | 69.42 ± 9.4 | 39.67 ± 9.3 | 27.98 ± 9.9 | 1.63 ±0.8 | 17.38 ±8.5 | 6.98 ± 4.4 | 8.27 ± 7.9 | 16.83 ±9.4 |
| Group 4 >200 | 10.09 ± 4.4 | 70.93 ± 7.9 | 42.31 ± 7.7 | 26.38 ±8.1 | 1.78 ±0.7 | 16.79 ± 7.2 | 6.73 ±4.5 | 6.77 ±6.7 | 15.54 ± 7.3* |
State of some immune parameters in NPP workers
*Significant difference in the average relative values of (CD57+ GD8+) was found between Group 1 and Group 4 (P= 0.040). Statistically significant differences compared with the control group are marked with bold type.
Frequency analysis of studied immune parameters in NPP workers given as a percentage of the number of subjects, who had cell counts under, within or above reference range
| Parameters | Dose (mSv) | Under the reference range (%) | Within the reference range (%) | Above the reference range (%) |
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 |
| CD 19+ | 0 (Control) | 7.8 | 87.5 | 4.7 |
| 0.1 – 20 | 12.6 | 80.6 | 6.8 | |
| 20.1 – 100 | 12.0 | 77.8 | 10.2 | |
| 100.1 – 200 | 10.6 | 75.8 | 13.6 | |
| >200 | 14.4 | 75.2 | 10.4 | |
| CD 3+ | 0 (Control) | 3.1 | 96.9 | - |
| 0.1 – 20 | 11.7 | 85.4 | 2.9 | |
| 20.1 – 100 | 13.7 | 84.6 | 1.7 | |
| 100.1 – 200 | 15.2 | 83.3 | 1.5 | |
| >200 | 10.5 | 86.9 | 2.6 | |
| CD4/CD8 index | 0 (Control) | 9.6 | 86.2 | 4.2 |
| 0.1 – 20 | 35.3 | 52.3 | 12.7 | |
| 20.1 –100 | 19.7 | 67.5 | 12.8 | |
| 100.1 – 200 | 30.3 | 60.6 | 9.1 | |
| >200 | 17.0 | 71.2 | 11.8 | |
| CD3+CD4+ | 0 (Control) | 3.2 | 95.4 | 1.4 |
| 0.1 – 20 | 28.2 | 68 | 3.8 | |
| 20.1 – 100 | 16.2 | 81 | 2.6 | |
| 100.1 – 200 | 24.2 | 75 | ||
| >200 | 9.8 | 87.6 | 2.6 | |
| CD3+ CD8+ | 0 (Control) | 4.6 | 90.8 | 4.6 |
| 0.1 – 20 | 13.6 | 69.9 | 16.5 | |
| 20.1 – 100 | 17.1 | 67.5 | 15.4 | |
| 100.1 – 200 | 13.6 | 68.2 | 18.2 | |
| >200 | 17.6 | 73.2 | 7.2 | |
| NK (CD3- CD16+ CD56+) | 0 (Control) | 6.2 | 83.0 | 10.8 |
| 0.1 – 20 | 9.7 | 72.8 | 17.5 | |
| 20.1 – 100 | 8.5 | 77.0 | 14.5 | |
| 100.1 – 200 | 4.5 | 77.3 | 18.2 | |
| >200 | 8.5 | 73.9 | 17.6 | |
| NKT (CD3+ CD16+ CD56+) | 0 (Control) | 0 | 85.4 | 14.6 |
| 0.1 – 20 | 0 | 77.8 | 22.2 | |
| 20.1 – 100 | 0 | 73.7 | 26.3 | |
| 100.1 – 200 | 0 | 72.7 | 27.3 | |
| >200 | 0 | 82.7 | 17.3 | |
| NK (CD57+ CD8-) | 0 (Control) | 6.6 | 88.5 | 4.9 |
| 0.1 – 20 | 6.4 | 74.5 | 19.1 | |
| 20.1 – 100 | 4.2 | 93.1 | 2.8 | |
| 100.1 – 200 | 3.7 | 88.9 | 7.4 | |
| >200 | 13 | 77.2 | 9.8 | |
| NKT (CD57+ CD8+) | 0 (Control) | 0 | 85.4 | 14.6 |
| 0.1 – 20 | 0 | 77.8 | 22.2 | |
| 20.1 – 100 | 0 | 73.70 | 26.3 | |
| 100.1 – 200 | 0 | 72.7 | 27.3 | |
| >200 | 0 | 82.7 | 17.3 |
Immune parameters changes in smoking and non-smoking persons
| Parameters | Under reference range % | Reference range % | Above reference range % | |||
|---|---|---|---|---|---|---|
| Non smokers | Smokers | Non smokers | Smokers | Non smokers | Smokers | |
| CD3+4+ % /p =0.026/ |
|
| 75.9 | 82.8 | 0.6 | 2.9 |
| CD3+8+ % /p =0.023/ | 10.5 | 13.7 | 69.1 | 76.0 |
|
|
| CD19+ abs/p=0.025/ | 12.3 | 7.9 | 82.7 | 79.9 |
|
|
| CD57+8+%/p=0.003/ | 3.8 | 1.5 | 16.8 | 31.0 |
|
|
Statistically significant differences compared with the control group are marked with bold type.